Table 1 of General characteristics patients with cancer complicated with IPE and SPE.
Characteristics | IPE, N = 88 | SPE, N = 92 | P-value |
|---|---|---|---|
Age, median (IQR), y | 61.0 (54–66) | 60 (53–68) | 0.934 |
Sex | Â | Â | 0.095 |
 Female | 35 (39.8) | 44 (47.8) |  |
 Male | 53 (60.2) | 48 (52.2) |  |
Location of the primary tumor | Â | Â | 0.298 |
 Lung | 33 (37.5) | 47 (51.1) |  |
 Digestive | 17 (19.3) | 16 (17.4) |  |
 Breast | 7 (7.9) | 10 (10.9) |  |
 Lymphoma | 12 (13.6) | 6 (6.5) |  |
 Melanoma | 8 (9.1) | 4 (4.3) |  |
 Urogenital | 8 (9.1) | 8 (8.7) |  |
 Others | 3 (3.4) | 1 (1.1) |  |
Cancer stage | Â | Â | 0.511 |
 I | 3 (3.4) | 3 (3.3) |  |
 II | 4 (4.5) | 1 (1.1) |  |
 III | 13 (14.8) | 17 (18.5) |  |
 IV | 68 (77.3) | 71 (77.2) |  |
ECOG PS |  |  | < 0.001* |
 0 | 29 (33.0) | 8 (8.7) |  |
 1 | 48 (54.5) | 43 (46.7) |  |
 2 | 9 (10.2) | 26 (28.3) |  |
 3 | 2 (2.3) | 10 (10.9) |  |
 4 | 0 (0.0) | 5 (5.4) |  |
Cancer treatment before PE | Â | Â | Â |
 Cytotoxic chemotherapy | 60 (68.2) | 53 (57.6) | 0.142 |
 Targeted chemotherapy | 29 (32.9) | 26 (28.3) | 0.494 |
 Immunotherapy | 4 (4.5) | 4 (4.3) | 0.436 |
 Hormonal therapy | 4 (4.5) | 8 (8.7) | 0.264 |
 Multiple treatment regimens | 31 (35.2) | 31 (33.7) | 0.829 |
 Radiotherapy | 14 (15.9) | 18 (19.6) | 0.622 |
Active cancer treatment before PE | Â | Â | Â |
 Cytotoxic chemotherapy | 48 (54.5) | 42 (45.6) | 0.233 |
 Targeted chemotherapy | 20 (22.7) | 24 (26.1) | 0.600 |
 Immunotherapy | 2 (2.3) | 4 (4.3) | 0.683 |
 Hormonal therapy | 1 (1.1) | 3 (3.3) | 0.621 |
 Multiple treatment regimens | 15 (17.0) | 12 (13.0) | 0.452 |
 Radiotherapy | 1 (1.1) | 0 (0.0) | 0.489 |